2025 Work Report of the Board of Directors
In 2025, the Board of Directors of Beijing Saisheng Pharmaceutical Co., Ltd. (hereinafter referred to as "the Company") strictly adhered to the Company Law of the People's Republic of China, the Securities Law of the People's Republic of China, the Management Measures for Information Disclosure of Listed Companies, the Listing Rules of the Shenzhen Stock Exchange for Growth Enterprises, the Self-Regulatory Guidelines No. 2 for the Standardized Operation of Growth Enterprise Listed Companies, the Self-Regulatory Guidelines No. 5 for Information Disclosure Affairs Management, as well as the Company’s Articles of Association and the Rules of Procedure for Board Meetings. All directors diligently fulfilled their responsibilities assigned by the shareholders' meeting, strictly executed the resolutions of the shareholders' meeting, effectively safeguarded the legitimate rights and interests of all shareholders and the Company, promoted standardized operations, and improved corporate governance levels. The main work report of the Board of Directors for 2025 is as follows:
1. Business Performance in 2025
In the current year, the Company achieved an operating income of 404.7184 million yuan, a decrease of 2.82% compared to the same period last year; the net profit attributable to shareholders of the listed company was 14.5710 million yuan, an increase of 121.16% compared to the same period last year. The Company's main business remained unchanged, focusing on three major product series: cardiovascular, immunomodulatory (anti-tumor), and neurological medications.
- Production Situation The Company maintained a record of zero safety production accidents and zero product quality incidents throughout the year. The production department strengthened quality management while encouraging comprehensive development among frontline employees, conducting regular skills assessments to enhance their technical and theoretical levels. Safety production meetings were held regularly, adhering to the safety principle of "safety first, prevention foremost," continuously improving the working environment and safety measures for employees. Through ongoing innovation and optimization of production processes, production efficiency steadily improved, while ensuring drug quality and reducing production costs.
The Company received a notice of compliance inspection for GMP (Good Manufacturing Practice) from the Beijing Drug Administration (Document No.: Jing Yao Jian Yao GMP [2024] 020143), indicating that the relevant products and production lines at the Liangshuihe Second Street plant met GMP requirements. The Company obtained a "Drug Production License" issued by the Beijing Drug Administration. The changes involved were approved by the Drug Review Center's technical review, allowing the production site for the injection of Buzhizhang peptide (National Drug Approval No. H11022156) to expand from the existing site at "No. 8 Xingsheng Street, Beijing Economic and Technological Development Zone" to include "No. 2 Courtyard B, Liangshuihe Second Street, Beijing Economic and Technological Development Zone (Small Volume Injection Production Workshop: X4 Line)." The renewed "Drug Production License" is valid until November 4, 2030.
- Sales Revenue and Contribution of Main Products During the reporting period, the proportion of revenue from fibrinolytic enzyme injections was 39.07%; GM1 accounted for 23.66%; sodium deoxyribonucleotide injections accounted for 16.79%; and Buzhizhang peptide injections accounted for 11.34%. In terms of gross profit margins, they ranked as follows: sodium deoxyribonucleotide injections at 80.15%; fibrinolytic enzyme injections at 79.74%; Buzhizhang peptide injections at 59.09%; and GM1 at 39.42%. The Company's overall gross profit margin was 65.11%. Compared to the previous year, the revenue proportion of fibrinolytic enzyme injections slightly decreased, while the gross profit margin increased by 1.56%; the revenue proportion of sodium deoxyribonucleotide injections slightly decreased, with a gross profit margin increase of 7.25%; the revenue proportion of Buzhizhang peptide injections slightly decreased, with a gross profit margin increase of 2.04%; and the revenue proportion of GM1 slightly increased, with a gross profit margin decrease of 1.26%.